Harmeet Singh, MD
Nephrology · Arvada, CONPI 1437140928
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,700 of the $4,039 with a category attached, or 66.8%. Travere Therapeutics, Inc. accounts for 95.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $3,826 and has fallen 98.7% since, to $49 in 2025.
Across 13 payments — averaging $310.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$4K
- Ardelyx, Inc.$121
- Biogen$31
- Amgen$28
- AbbVie$15
Across 172 payments — averaging $3033.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$241K
- AstraZeneca$222K
- Biogen$52K
- Gilead$7K
What the payments were for
- Consulting fees$2,70067%
- Travel & lodging$82921%
- Food & beverage$51013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 9 | $3,845 |
| Ardelyx, Inc. | 1 | $121 |
| Biogen | 1 | $31 |
| Amgen | 1 | $28 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$121
How this compares
$4,039 in reported general payments places this provider in the 80th percentile of 152 nephrology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 29 | $1,802 |
| Eplerenone | 26 | $1,592 |
| Calcium Acetate | 13 | $1,428 |
| Cyclosporine ModifiedCyclosporine, Modified | 15 | $1,406 |
| Potassium Citrate ErPotassium Citrate | 12 | $971 |
| Calcitriol | 23 | $658 |
| Potassium Chloride | 15 | $624 |
| Chlorthalidone | 34 | $557 |
| Hydralazine Hcl | 33 | $529 |
| Atorvastatin Calcium | 44 | $492 |
| Losartan Potassium | 43 | $374 |
| Prazosin Hcl | 11 | $359 |
| Furosemide | 28 | $328 |
| Amlodipine Besylate | 49 | $305 |
| Lisinopril | 58 | $301 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Arvada
- Rajesh YalavarthyArvada$8K
- Geoffrey BlockLone Tree$726K
- Laura KooiengaDenver$82K
- Brad MarderDenver$77K
- Richard JohnsonAurora$62K
- Maria VelezDenver$47K
- Paul MillerGolden$42K
- Bruce KaplanAurora$42K
- Michael ShomakerThornton$41K
- Sixto GiustiAurora$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.